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Abstract 
Platelets may have an important role in development of cardiovascular disease (CVD) as a 
result of chronic stress. We conducted a pilot study to evaluate the effect of posttraumatic 
stress disorder (PTSD) on baseline platelet activation. Platelet-leukocyte aggregates (PLA) 
and CD63 expression were measured by flow cytometry and soluble (s)P-selectin 
concentration was determined in sera of 20 Croatian male combat veterans with PTSD and 20 
healthy civilians. Groups were matched in sex, age, body mass index (BMI) and traditional 
CVD risk factors. Our data showed no differences in measured parameters. Other platelet 
activation markers should be determined and bigger sample size used in our future study. 
 
Keywords: war veterans, cardiovascular disease, flow cytometry 
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1. Introduction 
Recent studies provide convincing evidence that psychosocial factors contribute to 
pathogenesis and expression of coronary artery disease (Rozanski et al., 2005). Similarly, the 
evidence linking exposure to traumatic stress and cardiovascular disease (CVD) is compelling 
and supported by different epidemiologic studies (Sibai et al., 1989; Falger et al., 1992; 
Boscarino and Chang, 1999). Platelets play an important role in pathogenesis of 
atherosclerosis and acute coronary syndromes through their thrombotic and proinflammatory 
properties (Furman et al., 1998; Nijm et al., 2005). Posttraumatic stress disorder (PTSD) and 
increased CVD risk may be connected through mechanisms of platelet activation with 
substantial impact of acute or chronic stress (Brydon et al., 2005), particularly depression 
(Bruce and Musselman, 2005). This association might be formed through increased 
sympathetic output associated with PTSD (Yehuda et al., 1992, 1998). Catecholamines bind 
to α2-adrenergic receptors on platelet surface with consequent platelet activation (von Kanel 
and Dimsdale, 2000). Platelet activation results in surface expression of the adhesion 
molecule P-selectin, which binds to the leukocyte receptor, P-selectin glycoprotein ligand 
(PSGL-1) leading to the formation of platelet-leukocyte aggregates (PLA) (Rinder et al., 
1991). If platelet activation occurs repeatedly, for example during hyperarousal episodes in 
PTSD patients, proinflammatory factors released from platelets bound to leukocytes could 
promote atherosclerosis (Nijm et al., 2005). Furthermore, importance of platelet physiology in 
PTSD patients is emphasized by studies of  platelet α-2 adrenergic receptors number and 
reactivity (Perry et al., 1987), platelet peripheral-type benzodiazepine receptor density 
(Gavish et al., 1996), cAMP activity (Lerer et al., 1987), serotonin measures (Cicin-Sain et 
al., 2000; Pivac et al., 2002) and monoamine oxidase activity (Kozaric-Kovacic et al., 2000). 
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We assumed that platelet activity might be elevated in PTSD patients and conducted a pilot 
study to determine baseline platelet function in war veterans diagnosed with combat-related 
chronic PTSD. Circulating PLA and platelet activation dependent marker CD63 (lysosomal 
glycoprotein GP53) expression were determined by flow cytometry, and soluble (s)P-selectin 
(platelet α-granule glycoprotein GP140) concentrations were measured in sera.  
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2. Methods 
A total of 40 men, i.e. 20 Croatian combat veterans with PTSD and 20 age-comparable 
healthy civilians with no combat experience participated in this study. Veterans were PTSD 
outpatients from Vrapče Psychiatric Hospital. The study was approved by the local ethics 
committee, and written informed consent was obtained from all subjects after the study design 
had been fully explained. All patients met ICD-10 PTSD criteria (World Health Organization, 
1992), official classification in Croatian psychiatric practice. For purposes of this study, the 
diagnosis of PTSD was made by DSM-IV (American Psychiatric Association, 1994) based 
Clinician-Administered PTSD Scale (CAPS-DX) (Blake et al., 1996). All 20 patients met 
DSM-IV criteria for chronic PTSD. The PTSD-group was relatively homogenous related to 
the severity of the illness. The average severity of PTSD was qualified as moderate (mean=4), 
according to CGI-S scale (Guy 1976). The specificities of clinical picture (frequency and 
intensity of all and selected PTSD symptoms during the period of one month and one week 
prior to rating) were determined by CAPS scale (reexperiencing (mean±SD, 18.50±2.21), 
avoidance/numbing (26.35±2.32), hyperarousal (15.85±3.65)). No psychiatric premorbidity or 
comorbidity, including depression, was found in PTSD group when entering this study. The 
study was carried out 9 to 15 (median=13) years after veterans' traumatic experience.  
Prior to blood drawing, healthy civilians were examined by experienced physician and 
relevant data for purposes of this study were recorded on basis of patients’ histories. They had 
negative history of any psychiatric disorder and no symptoms or signs of acute or chronic 
physical illness other than conditions that were controlled for (Table 1).  
All participants were free of any psychotropic medication, drug or alcohol abuse for at least 
one month, and did not suffer from any infectious or allergic disorder. They had negative 
history of myocardial infarction, stable, non-stable angina pectoris or stroke. During the seven 
days prior to study, they haven’t used any non-steroid anti-inflammatory drugs. 
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Peripheral blood was collected by venipuncture using 4.5 mL sodium citrate, theophyilline, 
adenosine and dipyridamole (CTAD) Vacutainer tubes (Becton Dickinson, Rutherford, NJ, 
USA) for CD63 and PLA determination. To minimize platelet activation during blood 
drawing, only a light tourniquet and 20-gauge needles were used and the first 10 mL of blood 
were discarded. Samples were processed within 30 minutes of collection. Sera for (s)P-
selectin determination were stored at -80°C until assayed.  
Flow cytometry was done with LSR II  flow cytometer (BD Biosciences, Mountain View, 
USA) and data were analyzed with FACSDiva  software (BD Biosciences). Standard filters 
and mirrors for fluorescein isothiocyanate (FITC), phycoerythrin (PE) and peridinin 
chlorophyll protein (PerCP) fluorescence analysis were used.  
For PLA determination we used previously described assay (Li et al., 1999) with 
modifications. Briefly, 10 µL of whole blood were added to 90 µL of phosphate-buffered 
saline (PBS) containing 2 µL of BD Simultest™ LeucoGATE™ (BD Biosciences, 
Heidelberg, Germany) (FITC-conjugated anti-CD45 and PE-conjugated anti-CD14) and 10 
µL of PerCP-conjugated anti-CD42a (BD Biosciences) (glycoprotein IX, platelet specific 
marker). Saturating amounts of antibodies were determined by titration using sample 
stimulated by 20 µM adenosine diphosphate (ADP). After incubation in the dark at room 
temperature (RT) for 20 minutes, samples were fixed using 900 µL of 0.5% formaldehyde 
saline.  By adjusting threshold to fluorescence channel 1 (FITC emission signal), cytometer 
was set to acquire only CD45 positive events (leukocytes) at flow rate of 30 events/second 
until at least 2000 CD14 events (monocytes) were acquired. Lymphocytes, monocytes, and 
neutrophils were discriminated according to their side scatter properties and CD45 expression. 
Proportions of CD42a positive events in monocyte, neutrophil and lymphocyte gates 
represented percentages of platelet-lymphocyte (P-Lym), platelet-monocyte (P-Mon) and 
platelet-neutrophil (P-Neu) aggregates. 
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For CD63 determination, whole blood samples were diluted 10 fold with PBS and 10 µL  
were added to 40 µL of PBS containing 5 µL of FITC-conjugated anti-CD63 (BD 
Biosciences) and 5 µL of  PerCP-conjugated anti-CD42a (BD Biosciences). Appropriate 
isotype controls (BD Biosciences) were used for discrimination of nonspecific binding. The 
samples were gently mixed and incubated in the dark at RT for 20 minutes and fixed with 450 
µL of 0.5% formaldehyde saline. Cytometer threshold was set in fluorescence channel 3 
(PerCP emission signal) in order to exclude all CD42a-negative events from analysis. A total 
of 20 000 CD42a-positive events were acquired at flow rate set on 300 events/second. 
Proportions of CD63 positive events were determined with 0.5% of nonspecific binding 
allowed.  
(s)P-selectin concentrations were measured using a commercially available immunoenzymatic 
method with the human (s)P-selectin kit (R&D Systems Inc., Minneapolis, USA). All samples 
were analyzed following the manufacturer's protocol. 
Statistical analyses were done using Fisher’s exact chi-square tests for categorical data. Non 
Gaussian numerical data were normalized, tested for multivariate normality using Mardia test 
and analyzed with MANCOVA controlling for age, BMI and smoking. Partial correlations 
were performed controlling for the same factors.  Power analysis was conducted for two-
sample Hotelling's T-squared test (variant of MANOVA used for comparison of two groups). 
All tests were considered significant if P<0.05.
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3. Results 
Results are summarized in Table 1. Groups were similar in all assessed characteristics except 
work status with more PTSD patients being retired and majority of healthy controls being 
employed. Traditional CVD risk factors (hypertension, hyperlipidaemia, diabetes, smoking) 
were equally distributed among groups.   
No significant differences in P-Mon, P-Neu, P-Lym, CD63 and (s)P-selectin were found 
between groups. Our sample sizes with 20 participants per group achieved only 18% power to 
detect an effect size of 0.26 which represents the differences between the group means of the 
five response variables, adjusted by the variance-covariance matrix. To achieve 80% power 
for given effect size, at least 98 patients per group are needed. Effect sizes for single 
parameters yielded 0.40 (95% confidence interval, -0.23 to 1.03) for P-Mon, 0.06 (-0.56 to 
0.68) for P-Gran, -0.32 (-0.95 to 0.30) for P-Lym, 0.04 (-0.58 to 0.66) for CD63 and -0.06 (-
0.68 to 0.56) for (s)P-selectin.  
No one of response variables correlated significantly with scores for avoidance/numbing 
cluster of symptoms (P-Mon, r=0.14, P=0.585; P-Gran, r=0.04, P=0.865; P-Lym, r=-0.19, 
P=0.465; CD63, r=-0.29, P=0.243; (s)P-selectin, r=-0.14, P=0.600). P-Lym were in negative 
correlation with reexperiencing scores (r=-0.55, P=0.022) and CD63 expression negatively 
correlated with hyperarousal scores (r=-0.51, P=0.036). Any other variable didn't correlate 
significantly either with reexperiencing scores (P-Mon, r=0.27, P=0.292; P-Gran, r=-0.24, 
P=0.346; CD63, r=0.02, P=0.943; (s)P-selectin, r=-0.10, P=0.694) or hyperarousal scores (P-
Mon, r=0.18, P=0.466; P-Gran, r=-0.09, P=0.717; P-Lym, r=-0.04, P=0.878; (s)P-selectin, 
r=0.39, P=0.124). 
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4. Discussion 
In this pilot study we have evaluated the effect of chronic combat-related PTSD on baseline 
platelet activity. Comparison with healthy civilians showed no group differences in measured 
parameters.  Platelets in PTSD patients served mainly as peripheral model for studying 
neurotransmitters and their receptors but, to our knowledge, a question of platelet activity 
hasn’t been addressed yet. Designed as a pilot, this study has low sample sizes resulting in 
low power to detect group differences. Although not statistically significant, these differences 
are possibly clinically important so we decided to report calculated effect sizes as guidance 
for further research of the subject.  
While earlier studies mainly measured quantity of soluble circulating factors (e.g. platelet 
factor 4, beta-thromboglobulin), flow cytometry is nowadays widely used to assess platelet 
function in psychiatric disorders. Whole blood flow cytometry enables direct analysis of 
platelet function in their physiological milieu with minimal manipulation, preventing in vitro 
platelet activation (Michelson et al., 2000). Thus, it can detect very small changes of platelet 
function in vivo. Right choice of surface or soluble marker of platelet activation is very 
important and depends on condition being studied. Although platelet surface P-selectin 
(CD62P) is very sensitive measure of platelet function, we preferred to measure its soluble 
fraction because it is known that platelets rapidly loose CD62P and maintain their function 
(Michelson et al., 1996). Although (s)P-selectin, because of its endothelial portion (Semenov 
et al., 1999), is not exclusive measure of platelet activity,  there is a strong evidence proving 
that changes in (s)P-selectin levels directly reflect platelet disturbances (Blann et al., 2003). 
We should note that serum values differ from plasma values of (s)P-selectin (Caine and 
Blann, 2003; Thom et al., 2004) and future studies should address citrated plasma 
concentrations to confirm our results.  
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Upon activation, a portion of surface CD62P is involved in formation of PLA. Beside serving 
as indirect measure of CD62P, PLA provide more accurate measure of platelet function 
(Michelson et al., 2001).  CD63 is another platelet surface activation dependent molecule 
possibly involved in interaction with leukocytes (Israels et al., 2001) and platelet spreading 
(Israels and McMillan-Ward, 2005). 
Flow cytometry studies of baseline platelet activity in other psychiatric disorders, particularly 
depression, demonstrated controversial results (von Kanel, 2004). Among various activation 
dependent markers studied, no elevation in baseline expression of platelet CD63 was found in 
depression (Walsh et al., 2002a; Lederbogen et al., 2004) or schizophrenia (Walsh et al., 
2002b). Unexpectedly, CD63 negatively correlated with hyperarousal scores in our study. 
Although not in line with hypothesis of platelet hyperactivity in PTSD patients, this finding, 
along with negative correlation of P-Lym with reexperiencing scores, suggests involvement of 
sympathetic nervous system in regulation of platelet function. This is further supported by 
absence of any correlation with avoidance/numbing scores. PLA have not been studied before 
in the context of psychiatric disease while (s)P-selectin has been measured only in depressed 
with cardiovascular disease (Serebruany et al., 2003; Pasic et al., 2004). Nevertheless, Steptoe 
et al. (2003) reported higher baseline PLA in men with lower socioeconomic status and 
attributed it to cumulative effect of frequent daily stress. Although possible influence of 
prolonged stress and frequent hyperarousal episodes in PTSD patients on baseline PLA 
wasn’t confirmed in this study, we have noticed that P-Mon tend to be higher in PTSD group 
with higher effect size (0.40) than other parameters.  
It is proposed that mechanisms linking mental stress and platelet activity might be mediated 
by activating properties of epinephrine and norepinephrine through α-2 receptors on platelets 
(Camacho and Dimsdale, 2000). This hypothesis is supported by findings of reduced number 
and increased reactivity of α-2 adrenergic receptors on platelets (Perry et al., 1987) and 
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elevated 24-hour urine epinephrine and norepinephrine values in PTSD patients (Yehuda et 
al., 1992). Moreover, numerous studies showed elevated basal cardiovascular activity in 
PTSD (Buckley and Kaloupek, 2001).   
Studies of baseline plasma catecholamine levels generally found no changes in PTSD 
(Southwick et al., 1999). Our results are in line with these findings suggesting that platelet 
activity is not substantially altered by catecholamine disturbances at baseline level. On the 
other hand, increased reactivity to internal or external trauma associated cues, both in terms of 
elevated catecholamine levels and physiological arousal, are common findings in PTSD 
(Blanchard et al., 1991). Since platelet activation changes are relatively short-lived with 
platelet life-span of approximately seven days, similar studies are needed to assess in vivo 
platelet reactivity to psychological stimuli or in vitro reactivity to various platelet agonists, 
especially catecholamines.  
Although this pilot study indicates that baseline platelet activity is not altered in PTSD, we are 
far from reaching final conclusion. Other platelet activation markers should also be 
investigated and, considering the magnitude of changes, bigger sample sizes used. If platelet 
function in PTSD patients reflects findings related to sympathetic nervous system activation, 
we can expect them to have exaggerated platelet reactivity to psychological stimuli or 
physiological agonists and this could contribute to enhanced CVD risk.  
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Table 1 
 
Participant characteristics and variables 
 
Variable PTSD (n=20) Healthy controls (n=20) P-valuea 
Age (years) 
BMI 
Documented Hypertensionb 
Hyperlipidaemia (total cholesterol >5 mmol/L)b 
Tobacco use 
Diabetes type IIb 
Marital status 
 Married 
 Unmarried/divorced/widower 
Education 
 Elementary school 
 High school 
 University education 
Work status 
 Employed 
 Retired 
 Unemployed 
45.3±8.2 
25.04±2.57 
3 (15) 
2 (10) 
13 (65) 
1 (5) 
 
10 (50) 
10 (50) 
 
2 (10) 
16 (80) 
2 (10) 
 
11 (55) 
8 (40) 
1 (5) 
42.8±10.4 
26.78±3.76 
6 (30) 
3 (15) 
9 (45) 
1 (5) 
 
15 (75) 
5 (25) 
 
1 (5) 
12 (60) 
7 (35) 
 
19 (95) 
1 (5) 
0 (0) 
0.396 
0.123 
0.451 
1.000 
0.341 
1.000 
0.191 
 
 
0.135 
 
 
 
0.008* 
P-Mon (%)c 
P-Neu (%)c 
P-Lym (%)c 
CD63 (%)c 
(s)P selectin (ng/mL)c 
5.23 (3.97-8.10) 
1.32 (0.99-1.55) 
0.85 (0.66-0.97) 
1.06 (0.65-1.36) 
172.8 (114.3-200.0) 
4.60 (2.83-6.95) 
1.22 (1.03-1.61) 
0.88 (0.76-1.09) 
0.91 (0.62-1.48) 
152.3 (128.2-184.9) 
 
 
Values are means ± SD, n(%) or medians (interquartile range). BMI = body mass index; P-Mon = platelet-
monocyte aggregates; P-Neu = platelet-neutrophil aggregates; P-Lym – platelet-lymphocyte aggregates; (s) 
= soluble 
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a Two-sided values obtained using Fisher’s exact test or t-test. 
 
b
 Participants were using appropriate therapy. 
 
c Initial values before transformation. Hotelling’s Trace= 0.034, F(5,31)=0.21, P=0.954 (performed on 
transformed values). Since MANCOVA wasn’t significant, no additional ANCOVAs were 
performed. 
 
*
 Statistically significant.  
